Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
|Videos|January 9, 2013
Emerging Therapies and Alternative Treatment Strategies
This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.
Advertisement
The video from The National Multiple Sclerosis Society discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5